CHICAGO — The first randomized trial to evaluate whether a multicancer early detection test using a blood sample could result in diagnosis at earlier stages yielded mixed results.
The NHS-Galleri trial did not meet its primary endpoint, failing to show a reduction in combined stage III/stage IV diagnoses of 12 prespecified cancer types.
However, analyses of secondary endpoints showed a reduction in stage IV cancers alone and increased detection of stage I/stage II cancers among trial participants screened with the multicancer early detection (MCED) test annually for 3 years compared with those

CHICAGO — Treating resected brain metastases with cesium-131 tile-based radiation therapy immediately after surgery significantly improved local recurrence and survival compared with standard of care.
The findings from a phase 3 randomized trial, presented at ASCO Annual Meeting, showed patients who received the tile therapy had a 93% improvement in surgical bed recurrence and a 41% improvement in OS vs. stereotactic radiation.
“Surprised and ecstatic,” Jeffrey S. Weinberg, MD, FAANS, FACS, professor of neurosurgery and deputy chair and vice-chair of clinical operations in the department of

CHICAGO — Omitting completion axillary lymph node dissection does not increase risk for death for patients with clinically node-negative breast cancer, but it does significantly improve arm distress.
Data from the randomized SENOMAC trial, presented at ASCO Annual Meeting, showed patients who did not undergo completion axillary lymph node dissection (cALND) after a sentinel lymph node biopsy showing up to two metastases had the same OS as those who did.
“It’s very reassuring,” Jana de Boniface, MD, PhD, adjunct professor in the department of medical epidemiology and biostatistics at Karolinska

CHICAGO — The addition of two agents to standard first-line treatment significantly improved PFS among patients with aggressive B-cell lymphomas, according to results of the randomized phase 3 frontMIND trial.
The combination of tafasitamab (Monjuvi, Incyte), lenalidomide and R-CHOP reduced risk for progression or death by 25% compared with R-CHOP alone among patients with newly diagnosed high-risk diffuse large B-cell lymphoma or high-grade B-cell lymphoma, data presented at ASCO Annual Meeting showed.
The findings — which showed consistent benefit across subgroups defined by clinical and

KIAWAH ISLAND, S.C. — Cataract surgery should be performed midway between any anti-VEGF injections a patient may be receiving, Steve Charles, MD, said at Kiawah Eye and Retina.
“I’ve heard people say ... ‘Just for your convenience, we'll do the injection while you're in the OR, having cataract surgery,’” Charles said during his presentation.
{{VIDEO}}
“It is absolutely incorrect to inject the day before or during cataract surgery or the day after,” he told Healio.
If a patient develops a condition such as toxic anterior segment syndrome or vasculitis postoperatively, there is no way to know if it